Liza Laws, Author at Labiotech.eu

News and Trends 29 Jun 2022

Encouraging results from respiratory diseases vaccine trial

A biopharmaceutical company developing vaccines against infectious diseases has announced positive results for people with life threatening respiratory diseases. Icosavax says that in an interim phase 1/1b trial its vaccine IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no […]

June 29, 2022 - 4 minutesmins - By Liza Laws

PBC clinical trials: Gannex doses first patient

News and Trends 29 Jun 2022

Deal to advance treatment for autoimmune disease worth $97M

MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […]

June 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Jun 2022

Companies unite to bolster diagnostics for cancer and liver disease

Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […]

June 28, 2022 - 2 minutesmins - By Liza Laws

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 28 Jun 2022

Breast cancer drug recommended for approval

A cancer drug from AstraZeneca and Daiichi Sankyo called Enhertu, that reduces the risk of disease progression or even death by 72%, has been recommended for approval in the European Union (EU). The drug containing trastuzumab deruxtecan is specifically engineered for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with […]

June 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Jun 2022

Biogen, citing insurance challenges, shutters one of its Aduhelm studies

A company says it was forced to end an observational trial of Alzheimer’s drug, Aduhelm, after a ruling by US federal insurance program, Medicare. Biogen said a recent coverage decision by Medicare has forced it to abandon the trial of the drug after enrolling just 29 participants. The company said it made the decision to […]

June 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 27 Jun 2022

Trial for adults with late onset Pompe disease halted due to serious adverse event

The US Food and Drug Administration (FDA) has placed a clinical hold on a trial being run for Astrellas Pharma Inc after one of the participants had a serious adverse event (SAE) of peripheral sensory neuropathy. Astrellas made the announcement after the trial, which is evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement in […]

June 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 27 Jun 2022

Covid vaccine granted marketing authorization in Europe

Specialty vaccine company, Valneva, has been given marketing authorization in Europe for its inactivated whole-virus COVID-19 vaccine VLA2001. This is a turnaround from the company’s situation in May of this year when the stock price was knocked down by 20% when gaining traction in the EU was proving to be a struggle. Despite authorization from […]

June 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 27 Jun 2022

Fermentation facility opens its doors in Wisconsin

A new fermentation facility producing food ingredients and cultures, bacterial cultures, and probiotics has been opened in Franksville, Wisc., by Cultures Supporting Life (CSL). The ingredients, cultures and probiotics produced will be used in dairy, food, dietary supplements, pharma, and agriculture. Kyle Griffiths, vice president of sales and marketing said: “The new production facilities located […]

June 27, 2022 - 2 minutesmins - By Liza Laws

More News! 24 Jun 2022

Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M

Global pharmaceutical company, Radius Health Inc, announced this week (June 23) that it has entered into a definitive agreement to be bought out by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million. Radius Health is a company focused on addressing unmet medical needs in the areas of bone […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Jun 2022

Study reveals progress for those with hepatitis B

A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Jun 2022

Covid and malaria vaccines on track for mass production in Rwanda

Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Evaxion Biotech picks candidate for lung cancer trial

A clinical-stage biotech company that specializes in developing AI-driven immunotherapies has chosen its product candidate for an upcoming clinical trial for patients with advanced lung cancer. Evaxion Biotech selected EVX-03 within its DNA technology platform to target a new indication based on what it said are very encouraging results from pre-clinical studies. EVX-03 is optimized […]

June 23, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Encouraging results from respiratory diseases vaccine trial

Deal to advance treatment for autoimmune disease worth $97M

Companies unite to bolster diagnostics for cancer and liver disease

Breast cancer drug recommended for approval

Biogen, citing insurance challenges, shutters one of its Aduhelm studies

Trial for adults with late onset Pompe disease halted due to serious adverse event

Covid vaccine granted marketing authorization in Europe

Fermentation facility opens its doors in Wisconsin

Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M

Study reveals progress for those with hepatitis B

Covid and malaria vaccines on track for mass production in Rwanda

Evaxion Biotech picks candidate for lung cancer trial

Subscribe to our newsletter to get the latest biotech news!